Abstract
Alzheimers disease (AD) is characterized by the presence of numerous neurofibrillary tangles and neuritic plaques in the neocortex, especially in the hippocampus. Besides there is ample evidence of disturbances of energy metabolism. Biochemical analyses demonstrated reduction of pyruvate dehydrogenase activity3 and abnormalities of the respiratory chain4,5 in post mortem brain tissue from AD patients. Point mutations in mtDNA, as it was shown for some other encephalomyo-pathies and neurodegenerative disorders6 are reported in about 50% of AD patients.7 Two types of mutations, both at mtDNA position 5460 in codon 331 of the ND2 gene, are described (Figure 1): a G4A transition converting the wildtype amino acid alanine to threonine and a G4T mutation converting alanine to serine. None of the controls showed these mutations. Analyses of Petruzzella et al.2 couldn’t confirm these findings, suggesting a neutral polymorphism not specifically related with AD. We report here the use of allele specific PCR to search for mutations at nt 5460 in post mortem brain and blood of AD patients and blood and muscle tissue of patients with presumed mitochondrial encephalomyopathies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
F.-H. Lin, R. Lin, H.M. Wisniewski, Y.-W. Hwang, I. Grundke-Iqbal, H.L. Healy-Louie, and K. Iqbal, Detection of point mutations in codon 331 of mitochondria) NADH dehydrogenase subunit 2 in Alzheimer’s brains, Biochem. Biophys. Res. Commun. 182: 238–246 (1992).
V. Petruzella, X. Chen, and E.A. Schon, Is a point mutation in the mitochondria) ND2 gene associated with Alzheimer’s disease, Biochem. Biophys. Res. Commun. 186: 491–497 (1992).
S. Sorbi, E.D. Bird, and J.P. Blass, Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain, Ann Neurol. 13: 72–78 (1983).
H. Reichmann, S. Flórke, G. Hebenstreit, H. Schrubar, and P. Riederer, Analyses of energy metabolism and mitochondria) genome in post-mortem brain from patients with Alzheimer’s disease, J. Neurol. 240: 377–380 (1993).
V.D. Parker, C.M. Filley, and J.K. Parks, Cytochrome oxidase deficiency in Alzheimer’s disPAse, Neurology 40: 1302–1303 (1990).
D.C. Wallace, Diseases of the mitochondria) DNA, Ann Rev Biochem. 61: 1175–1212 (1992).
P. Lestienne, I. Nelson, P. Riederer, K. Jellinger, and H. Reichmann, Normal mitochondria) genome in brain from patients with Parkinson’s disease and complex I defect, J. Neurochem. 55: 1810–1812 (1990).
S.R. Hammans, M.G. Sweeney, M. Brockington, J.A. Morgan-Hughes, and A.E. Harding, Mitochondria) encephalopathies–molecular genetic diagnosis from blood samples, Lancet. i: 1311–1313 (1991).
F. Sanger, S. Nicklen, and A.R. Coulson, DNA sequencing with chain-terminating inhibitors, Proc. Natl. Acad Sci USA. 74: 5463–5467 (1977).
P. Seibel, F. Degoul, N. Romero, C. Marsac, and B. Kadenbach, Identification of point mutations by mispairing PCR as exemplified in MERRF disease, Biochem. Biophys. Res. Commun. 173: 561–565 (1990).
F.-H. Lin, and R. Lin, A comparison of single nucleotide primer extension with mispairing PCR-RFLP in detecting a point mutation, Biochem. Biophys. Res. Commun. 189: 1202–1206 (1992).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Janetzky, B., Schmid, C., Riederer, P., Reichmann, H. (1995). Is the Point Mutation in Codon 331 of the Mitochondrial ND2 Gene Associated with Alzheimer’s Disease?. In: Hanin, I., Yoshida, M., Fisher, A. (eds) Alzheimer’s and Parkinson’s Diseases. Advances in Behavioral Biology, vol 44. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9145-7_99
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9145-7_99
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9147-1
Online ISBN: 978-1-4757-9145-7
eBook Packages: Springer Book Archive